Liu et al. identified HER2 as an ST6GAL1 substrate and showed that HER2 α-2,6 sialylation confers protection against trastuzumab-mediated apoptosis through AKT and ERK1/2 pathway in gastric cancer cells [111]. The gene discussed is ERBB2; the disease is gastric cancer.